This story was originally posted on March 15.

A federal jury decided last week that Illumina has infringed a patent held by Syntrix Biosystems and ordered Illumina to pay Syntrix $96 million, based on a 6 percent royalty rate for Illumina BeadChip products sold between 2005 and May 2012.

Illumina CEO Jay Flatley said in a statement that the firm "strongly disagrees" with the decision and plans to appeal it, and will also continue to sell the BeadChip products that are the subject of the suit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.